Table 4 Comparison between vaccine nonavalent and quadrivalent, considering all positive HPV patients and all subgroups defined in this study.
Vaccine quadrivalent genotype | Vaccine nonavalent genotype | Quadrivalent vs. Nonavalent p-value (p) | |
|---|---|---|---|
All HPV positive patients (572) | |||
Vaccine impact | |||
Low Impact | 19.8% (113/572) | 29.7% (170/572) | 19.8% < 29.7%, p* < 0.0001 (M) |
High Impact | 26.6% (152/572) | 34.6% (198/572) | 26.6% < 34.6%, p* < 0.0001 (M) |
Group I 138 positive HPV patients | |||
Vaccine impact | |||
Low Impact | 29.7% (41/138) | 35.5% (49/138) | 29.7% < 35.5%, p* = 0.0078 (M) |
High Impact | 28.3% (39/138) | 32.6% (45/138) | 28.3% < 32.6%, p = 0.146 (M) |
Group II 137 positive HPV patients | |||
Vaccine impact | |||
Low Impact | 19.7% (27/137) | 31.4% (43/137) | 19.7% < 31.4%, p* < 0.0001 (M) |
High Impact | 31.4% (43/137) | 38% (52/137) | 31.4% < 38%, p = 0.0931 (M) |
Group III 297 positive HPV patients | |||
Vaccine impact | |||
Low Impact | 15.1% (45/297) | 26.3% (78/297) | 15.1% < 26.3%, p* < 0.0001 (M) |
High Impact | 23.2% (69/297) | 33.7% (100/297) | 23.2% < 33.7%, p* < 0.0001 (M) |
